FDA Approves the First New Schizophrenia Drug in Decades
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...
Severity of various FDA product recalls including Class I which can cause death, serious illness
Hundreds of foods are recalled by the FDA every year. Food recalls could fall into different categories, depending on how ...
FDA Approves New Schizophrenia Drug in 70-Year First
The treatment offers hope to thousands of patients who do not respond to existing medications, and has shown promise in treating other neurological disorders.
US’ first self-administered flu vaccine could increase accessibility and uptake
FluMist’s approval for self- or caregiver-administration provides patients with increased accessibility to the seasonal ...
Managed Healthcare Executive55m
FDA Approves the Oral Medication KarXT for Schizophrenia
KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually. The drug represents a new way to treat adults with schizophrenia.
Plastics News52m
Aptar works with FDA on chemical-absorbing film, expands in New York
The U.S. Food & Drug Administration has accepted Aptar Pharma's N-Sorb nitrosamine mitigation solution into its Emerging ...
The Financial Express34m
Bristol Myers gets USFDA nod for new type of schizophrenia drug
Schizophrenia causes persistent delusions and hallucinations and significantly impairs the way patients perceive reality.
Establishment Labs Jumps In Pre-market On FDA Approval Of Its Motiva Breast Implants
Shares of Establishment Labs Holdings Inc. (ESTA) were surging more than 21 percent in pre-market on Friday to $50.22, after its ...
Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day
Announces completion of enrollment in its oral allergen challenge study for the development of its late-stage pipeline program, Anaphylm™ ...
Bristol Myers Stock Jumps. Why FDA Approval for Its Schizophrenia Drug Is Groundbreaking.
Bristol Myers Squibb stock jumped after the pharma company won approval for its new schizophrenia drug late Thursday. “This ...
technologynetworks9m
FDA Approves First Schizophrenia Treatment With a Novel Target in 70 Years
The US Food and Drug Administration has granted approval to Bristol-Myers Squibb’s drug Cobenfy® (xanomeline and trospium ...